Why the study?
Does dexrazoxane prevent subclinical cardiotoxicity in multiple sclerosis patients receiving mitoxantrone?
Does dexrazoxane prevent subclinical cardiotoxicity in multiple sclerosis patients receiving mitoxantrone?
Dexrazoxane significantly reduces the decline in left ventricular ejection fraction associated with mitoxantrone therapy in multiple sclerosis patients.
Answers are grounded in this paper and cite their sources.
May attenuate mitoxantrone-related LVEF decline in MS; hypothesis-generating and requires RCTs before practice change.
OBJECTIVE: To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. METHODS: An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. RESULTS: No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, -3.80% vs -8.55%, p < 0.001). INTERPRETATION: These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
No takes yet. Share an insight, caveat, or question.
Bernitsas et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: